Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)

NCT: NCT04871035 · RECRUITING

NCT IDNCT04871035
StatusRECRUITING
Start Date2021-04-28
Completion2027-09-01

Brief Summary

This is an observations study evaluating safety and efficacy of immunoadsorption compared to plasma exchange in Guillain-Barré Syndrome.

Frequently Asked Questions

What is Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)?

Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS) is a clinical trial registered under NCT04871035. Current status: RECRUITING.

What is the status of NCT04871035?

The current status of NCT04871035 (Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)) is: RECRUITING.

When did Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS) start?

Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS) started on 2021-04-28.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑